• Overview
  Quotes Prices Key Stats News Press Releases Sentiment
• Charts
  Chart Technicals
• Company
  Splits Dividends Recommendations Price Target Insider Trades Holders Peers Filings Notes due Fail to deliver ESG Score Executive Compensation Profile
• Earnings
  Price Reaction Earnings Estimates Trends Call Transcripts
• Financials
  Fundamentals DCF Beta
• Analysis
  Up/Down Intra-day Events Performance Recovery Returns Price Distribution Unusual Volume Best Days Data Correlations Seasonality Volatility Trader Stats

Summary

News

09/16 08:00 EST - globenewswire.com
Provident Bank Announces $88,000 in Grants to Nine New Jersey Non-Profit Organizations
Funding is provided through the bank's Community Partnership Program Funding is provided through the bank's Community Partnership Program

08/20 11:36 EST - seekingalpha.com
Readers Identify 25 Ideal July Dividend Buys Out Of 37 Picks
Before July 31, 2024, my REaders mentioned 38 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: FSK, PFE, VZ, PFS, PBR, ET, ESEA, EL, VALE, and NOAH averaged 41.06% net gains from reader data collected 8/14/24. Ten analyst-target-augured July TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: XOM, PBR, PFE, VZ, PFS, ET, ESEA, EL, VALE & NOAH, boasting a 33.38% average target price upside estimate.

08/08 04:00 EST - prnewswire.com
New Pacific Metals Announces Filing of NI 43-101 PFS Technical Report for the Silver Sand Project
VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ - New Pacific Metals Corp. (TSX: NUAG) (NYSE-A: NEWP) ("New Pacific" or the "Company") is pleased to report the filing of an independent Pre-Feasibility Study ("PFS") technical report for its Silver Sand project (the "Project") located in Potosi, Bolivia with an effective date of June 19, 2024 (the "PFS Technical Report"). The PFS Technical Report was prepared in accordance with the Canadian Securities Administrators' National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101").

08/01 03:29 EST - seekingalpha.com
Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks
I have a diversified portfolio of stocks, funds, and bonds. My stocks are primarily dividend paying value stocks. One can find dividend stocks with superior estimated total returns by comparing their return drivers – earnings growth, dividend yield and valuation - to historic trends. This article compares the earnings growth, dividend yield, current valuation, and estimated future return of 53 stocks.

07/31 08:00 EST - globenewswire.com
Provident Bank Welcomes Leonardo Ramos As Vice President, CRA Officer
ISELIN, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Provident Bank ,  a leading New Jersey-based financial institution, is pleased to welcome Leonardo Ramos as Vice President, Community Reinvestment Act (CRA) Officer.

07/26 13:40 EST - seekingalpha.com
Provident Financial Services, Inc. (PFS) Q2 2024 Earnings Call Transcript
Provident Financial Services, Inc. (NYSE:PFS ) Q2 2024 Results Conference Call July 26, 2024 10:00 AM ET Company Participants Adriano Duarte - Head of Investor Relations Tony Labozzetta - President and CEO Tom Lyons - Senior EVP, CFO Conference Call Participants Mark Fitzgibbon - Piper Sandler Tim Switzer - KBW Billy Young - RBC Capital Markets Operator [Call Started Abruptly] I would now like to turn the call over to Adriano Duarte, Head of Investor Relations. Adriano. Please go ahead.

07/25 20:35 EST - zacks.com
Provident Financial (PFS) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Provident Financial (PFS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07/25 17:25 EST - globenewswire.com
Provident Financial Services, Inc. Reports Second Quarter 2024 Results Inclusive of Merger-Related Costs and Declares Quarterly Cash Dividend
ISELIN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) reported a net loss of $11.5 million, or $0.11 per basic and diluted share for the three months ended June 30, 2024, compared to net income of $32.1 million, or $0.43 per basic and diluted share, for the three months ended March 31, 2024 and $32.0 million, or $0.43 per basic and diluted share, for the three months ended June 30, 2023. For the six months ended June 30, 2024, net income totaled $20.6 million, or $0.23 per basic and diluted share, compared to $72.5 million, or $0.97 per basic and diluted share, for the six months ended June 30, 2023.

07/18 07:56 EST - globenewswire.com
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 18, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report significantly higher PFS for its top responder patient in the Phase 2 study of BriaCell's Bria-IMT™ regimen in combination with an immune checkpoint inhibitor in metastatic breast cancer. The patient remains alive and she continues to receive BriaCell's treatment regimen.

07/12 12:45 EST - zacks.com
Strength Seen in Provident Financial (PFS): Can Its 5.7% Jump Turn into More Strength?
Provident Financial (PFS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

07/05 01:00 EST - globenewswire.com
FDA approves Roche's Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet' age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect close to 80 million people globally.1-4 The Vabysmo PFS will become available to United States (US) retina specialists and their patients in the coming months.

07/05 01:00 EST - businesswire.com
FDA Approves Genentech's Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) has approved the Vabysmo® (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect close to three million.

06/24 09:40 EST - zacks.com
Best Income Stocks to Buy for June 24th
PFS, BFS and GPRK made it to the Zacks Rank #1 (Strong Buy) income stocks list on June 24, 2024.

06/21 08:48 EST - seekingalpha.com
70 All-Star And Graham Value Stocks: 57 Fit To Buy In June
Large Cap Value rankings from YCharts identify stocks with low prices relative to their assets and profits. The Ben Graham Formula strategy selects stable stocks with strong earnings and dividends based on Graham's book "The Intelligent Investor". 57 out of 70 All-Star-Value Dividend stocks offer annual dividends (from $1K invested) exceeding their price per share.

05/31 09:14 EST - globenewswire.com
Surge Copper Announces Closing of $3.9M Strategic Placement and Commences Berg PFS Metallurgical Test Program
Vancouver, British Columbia, May 31, 2024 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG ) (OTCQB: SRGXF ) (Frankfurt: G6D2 ) (“Surge” or the “Company”) is pleased to announce that it has closed its previously announced strategic placement (the “Strategic Placement”) (see April 2, 2024 press release) for gross proceeds of approximately $3.9 million. In addition, the Company announces that it has completed sample selection and shipped the sample material to commence a pre-feasibility study (“PFS”) metallurgy program for the Berg Project.

05/30 14:29 EST - businesswire.com
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-cen.

05/28 09:10 EST - zacks.com
5 Reasons to Buy Provident Financial (PFS) Stock Right Now
Strategic acquisition of Lakeland Bancorp, high rates, modest loan demand and robust balance sheet will keep supporting Provident Financial (PFS). This makes PFS stock an attractive pick.

05/24 08:00 EST - globenewswire.com
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces positive clinical data of its lead product candidate, Bria-IMT™, to be presented in one oral presentation session (by Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD), two poster sessions, and one abstract on the updated clinical data of BriaCell's randomized Phase 2 study evaluating Bria-IMT™ in patients with advanced metastatic breast cancers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place taking place May 31 - June 4, 2024 at McCormick Place, Chicago, IL. The abstracts for these presentations are now available at https://conferences.asco.org/am/abstracts.

05/20 13:06 EST - zacks.com
Provident Financial (PFS) Closes Merger With Lakeland Bancorp
Provident Financial (PFS) completes its previously announced merger with Lakeland Bancorp to form a super-community bank in New Jersey.

05/20 07:14 EST - https://www.defenseworld.net
Devon Energy Co. (NYSE:DVN) Stake Boosted by Panagora Asset Management Inc.
Panagora Asset Management Inc. lifted its stake in Devon Energy Co. (NYSE:DVN – Free Report) by 151.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,522 shares of the energy company’s stock after acquiring an additional 39,449 shares during the quarter. Panagora Asset Management Inc.’s holdings in Devon Energy were worth $2,968,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds and other institutional investors have also modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Devon Energy during the 3rd quarter worth about $27,000. Sound Income Strategies LLC increased its stake in shares of Devon Energy by 60.7% during the 4th quarter. Sound Income Strategies LLC now owns 675 shares of the energy company’s stock worth $31,000 after purchasing an additional 255 shares during the last quarter. Rise Advisors LLC raised its holdings in shares of Devon Energy by 1,365.3% during the 4th quarter. Rise Advisors LLC now owns 718 shares of the energy company’s stock valued at $33,000 after purchasing an additional 669 shares in the last quarter. PFS Partners LLC acquired a new stake in shares of Devon Energy in the 4th quarter valued at $36,000. Finally, Naples Money Management LLC bought a new stake in Devon Energy in the fourth quarter worth $40,000. 69.72% of the stock is currently owned by hedge funds and other institutional investors. Devon Energy Price Performance Shares of NYSE:DVN opened at $49.62 on Monday. The business’s 50 day moving average is $50.70 and its 200-day moving average is $46.45. The company has a current ratio of 1.04, a quick ratio of 0.97 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $31.36 billion, a PE ratio of 9.47 and a beta of 2.16. Devon Energy Co. has a 1-year low of $40.47 and a 1-year high of $55.09. Devon Energy (NYSE:DVN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The energy company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.06. Devon Energy had a net margin of 22.27% and a return on equity of 29.02%. The firm had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.64 billion. During the same quarter in the previous year, the firm posted $1.46 EPS. The business’s revenue for the quarter was down 5.9% on a year-over-year basis. Sell-side analysts predict that Devon Energy Co. will post 5.21 earnings per share for the current year. Devon Energy Cuts Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 14th will be paid a $0.22 dividend. The ex-dividend date is Friday, June 14th. This represents a $0.88 dividend on an annualized basis and a yield of 1.77%. Devon Energy’s payout ratio is currently 16.79%. Insiders Place Their Bets In other news, EVP Tana K. Cashion sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $51.04, for a total value of $1,020,800.00. Following the sale, the executive vice president now directly owns 104,182 shares in the company, valued at approximately $5,317,449.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.63% of the company’s stock. Wall Street Analyst Weigh In DVN has been the subject of a number of analyst reports. UBS Group boosted their price target on Devon Energy from $48.00 to $57.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 10th. Mizuho upped their target price on Devon Energy from $57.00 to $61.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Piper Sandler increased their price target on Devon Energy from $60.00 to $61.00 and gave the company an “overweight” rating in a report on Tuesday, May 14th. Royal Bank of Canada boosted their price objective on shares of Devon Energy from $55.00 to $57.00 and gave the stock a “sector perform” rating in a research note on Thursday, May 9th. Finally, Citigroup raised their target price on shares of Devon Energy from $55.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.83. Read Our Latest Stock Report on DVN Devon Energy Company Profile (Free Report) Devon Energy Corporation, an independent energy company, engages in the exploration, development, and production of oil, natural gas, and natural gas liquids in the United States. It operates in Delaware, Eagle Ford, Anadarko, Williston, and Powder River Basins. The company was founded in 1971 and is headquartered in Oklahoma City, Oklahoma. See Also Five stocks we like better than Devon Energy Stock Average Calculator JD’s Earnings Could Mean Chinese Stocks Making a Comeback Stock Trading Terms – Stock Terms Every Investor Needs to Know Canada Goose Flies Higher Driven By DTC Growth How to Know if a Stock Pays Dividends and When They Are Paid Out CVS Health Stock Has a Silver Lining Called Value